Search

Your search keyword '"Iluvien (Medication)"' showing total 516 results
Start Over Descriptor "Iluvien (Medication)"
516 results on '"Iluvien (Medication)"'

1. Q2 2024 ANI Pharmaceuticals Inc Earnings Call - Final

Subjects
ANI Pharmaceuticals Inc., Pharmaceutical industry, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. second quarter 2024 earnings results call. Please note this call is being recorded. (Operator Instructions) It is now [...]

Published
2024

2. Alimera Sciences reports Q1 EPS (12c), consensus (6c)

Subjects
Company earnings/profit, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Reports Q1 revenue $23.011M, consensus $22.25M. 'Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and support the acceleration [...]

Published
2024

3. ANI Pharmaceuticals Inc will Acquire Alimera Sciences Inc M&A Call - Final

Subjects
ANI Pharmaceuticals Inc. -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the ANI Pharmaceuticals conference to discuss acquisition of Alimera Sciences. (Operator Instructions) Please note today's call will be recorded, and I'll be standing [...]

Published
2024

4. Q1 2024 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences first-quarter and 2024 financial results and corporate update conference call. (Operator Instructions) [...]

Published
2024

5. Alimera Sciences Updates on Fourth Quarter and Full Year 2023 Results

Subjects
Company earnings/profit, Arts and entertainment industries, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera Sciences, a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, reported financial results for [...]

Published
2024

6. Q4 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences fourth quarter and fiscal year 2023 financial results and corporate update conference [...]

Published
2024

7. Alimera Sciences reports Q3 EPS (6c), consensus (6c)

Subjects
Company earnings/profit, Business, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

Reports Q3 revenue $23.4M, consensus $22.72M. 'We are pleased to announce record net revenue of $23.4 million, a significant decrease in our net loss and record Adjusted EBITDA in our [...]

Published
2023

8. Alimera Sciences expects top-lined data from NEW DAY study in 1Q25

Subjects
Medical research, Medicine, Experimental, Fluocinolone acetonide, Vascular endothelial growth factor, Fluocinolone, Business, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera's overenrolled NEW DAY Study evaluating ILUVIEN's utility as baseline therapy head-to-head versus the leading anti-VEGF in the treatment of diabetic macular edema has completed enrollment with 306 patients and [...]

Published
2023

9. ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Subjects
ANI Pharmaceuticals Inc. -- Mergers, acquisitions and divestments, Diseases -- United States, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, General interest, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

PRINCETON: ANI Pharmaceuticals, Inc. announced they have signed a definitive agreement under which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value [...]

Published
2024

10. ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Subjects
United States. Securities and Exchange Commission, ANI Pharmaceuticals Inc., Diseases -- United States, Pharmaceutical industry, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue [...]

Published
2024

11. Q3 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences third-quarter 2022 (sic - 2023) financial results and corporate update conference call. [...]

Published
2023

12. Alimera Sciences completes recruitment for NEW DAY study

Subjects
Vascular endothelial growth factor, Industry hiring, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that it has completed enrollment for the company's NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN 0.19 mg as [...]

Published
2023

13. Alimera Sciences announces expansion of agreement with Horus Pharma

Subjects
Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that it has further expanded its relationship with Horus Pharma, one of the Company's current distributors of ILUVIEN in Europe. Alimera and Horus have agreed to expand [...]

Published
2023

14. Alimera Sciences Releases Financial Performance for Q4 and FY 2023

Subjects
General interest, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera Sciences, Inc. (Alimera) has announced its financial results for the fourth quarter and full year 2023. The company's net revenue increased by 88% to approximately $26.3 million in Q4 [...]

Published
2024

15. Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE [...]

Published
2024

16. The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN(r)

Subjects
Dropsy -- Care and treatment, Fluocinolone acetonide, Edema -- Care and treatment, Fluocinolone, General interest, News, opinion and commentary, Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision [...]

Published
2024

17. The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN(R)

Subjects
Dropsy -- Care and treatment, Fluocinolone acetonide, Edema -- Care and treatment, Fluocinolone, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2024

18. Q2 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Second Quarter 2023 Financial Results Conference Call. (Operator Instructions) Participants of this [...]

Published
2023

19. Q1 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Investor relations, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Corporate Update Conference Call. (Operator Instructions) Participants of this call are advised [...]

Published
2023

20. Alimera announces reimbursement of uveitis indication granted to ILUVIEN

Subjects
Uveitis, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN 0.19 mg sustained release intravitreal implant for non-infectious uveitis, through its distribution [...]

Published
2022

21. Alimera Sciences says ILUVIEN patients show reduced need for multiple treatments

Subjects
Vascular endothelial growth factor, Lasers in surgery, Lasers in medicine, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announced that post-hoc analyses from the PALADIN Phase 4 Safety Study demonstrate that median treatment frequency in diabetic macular edema patients treated with the ILUVIEN 0.19 mg was [...]

Published
2022

22. Alimera Announces Scientific Data Highlighting ILUVIEN(r) To Be Presented at the American Academy of Ophthalmology

Subjects
Fluocinolone acetonide, Ophthalmology, Fluocinolone, General interest, News, opinion and commentary, American Academy of Ophthalmology, Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc. has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

Published
2023

23. Alimera Announces Scientific Data Highlighting ILUVIEN(R) To Be Presented at the American Academy of Ophthalmology

Subjects
Fluocinolone acetonide, Ophthalmology, Fluocinolone, Banking, finance and accounting industries, Business, American Academy of Ophthalmology, Iluvien (Medication)
Abstract

ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2023

24. Alimera Sciences Announce Third Quarter 2023 Results

Subjects
Company earnings/profit, General interest, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced [...]

Published
2023

25. Alimera Sciences Reports Third Quarter 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Net Revenue up 72% to $23.4 Million vs. Q3 2022 Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022 Adjusted EBITDA of $5.4 Million in Q3 2023 Successful [...]

Published
2023

26. Alimera Announces Multiple Presentations Highlighting ILUVIEN(r) and YUTIQ(r) Data at Retina Society Annual Congress

Subjects
Fluocinolone acetonide, Fluocinolone, General interest, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc. has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

Published
2023

27. Alimera Announces Multiple Presentations Highlighting ILUVIEN(R) and YUTIQ(R) Data at Retina Society Annual Congress

Subjects
Medical research, Medicine, Experimental, Societies, Fluocinolone acetonide, Fluocinolone, Associations, institutions, etc., Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2023

28. Durable therapies for diabetic macular edema amid COVID-19 pandemic: Patients' reluctance to visit clinic pushes retina specialists to optimize therapy

Author

Luo, Caesar K.

Subjects
Epidemics -- Care and treatment, Dropsy -- Care and treatment, Diabetes therapy, Vascular endothelial growth factor, Fluocinolone acetonide, Edema -- Care and treatment, Fluocinolone, Health, Iluvien (Medication)
Abstract

During the earliest stages of the COVID-19 pandemic, some patients with diabetic macular edema (DME) were reluctant to visit the office for therapy or monitoring. The risks of complications secondary [...]

Published
2021

29. Q4 2022 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences 2022 Financial Results Conference Call. (Operator Instructions) Participants of this call are [...]

Published
2023

30. Alimera announces agreement with JCHR for health research

Subjects
Fluocinolone acetonide, Fluocinolone, Company business planning, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation, JCHR, acting on the behalf of the DRCR Retina Network to support [...]

Published
2022

31. Alimera reimbursement of uveitis indication granted for ILUVIEN in Ireland

Subjects
Uveitis, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior [...]

Published
2022

32. Alimera announces reimbursement of uveitis indication granted for ILUVIEN

Subjects
Uveitis, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior [...]

Published
2022

33. Alimera Sciences announces subsidiary to launch ILUVIEN in France

Subjects
Diseases -- Relapse, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch ILUVIEN for non-infectious posterior uveitis in France, through its distribution partner, Horus Pharma S.A.S.. Horus has [...]

Published
2022

34. Alimera announces approval and pricing granted for Iluvien for uveitis in Italy

Subjects
Diseases -- Relapse, Fluocinolone acetonide, Uveitis, Fluocinolone, Pharmaceuticals and cosmetics industries, Iluvien (Medication)
Abstract

Alimera Sciences, Inc. (Alimera), a global pharmaceutical company, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval, including a positive determination for the pricing and reimbursement, [...]

Published
2022

35. Alimera Sciences announces approval, pricing granted for ILUVIEN in Italy

Subjects
Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval, including a positive determination for the pricing and reimbursement, for ILUVIEN for the prevention of [...]

Published
2022

36. Q3 2022 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporate Update Conference Call. (Operator Instructions) [...]

Published
2022

37. Alimera notes positive predictive value of corticosteroids before Iluvien

Subjects
Fluocinolone acetonide, Ophthalmology, Fluocinolone, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN U.S. label to mitigate the risk [...]

Published
2022

38. Alimera Sciences announces abstracts on ILUVIEN at ARVO conference

Subjects
Fluocinolone acetonide -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Alimera Sciences announced that ILUVIEN will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology, ARVO, conference being held in Denver, Colorado from [...]

Published
2022

39. Alimera Sciences Reports Second Quarter 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera Acquired U.S. Commercial Rights to YUTIQ [sup. (R) ] Landmark NEW DAY Study Completed Enrollment with over 300 Patients Consolidated Net Revenue of $17.5 Million Up 20% vs. Second [...]

Published
2023

40. Alimera Sciences Delivers Second Quarter 2023 Results

Subjects
Company earnings/profit, General interest, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced financial [...]

Published
2023

41. Q2 2022 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Science Second Quarter 2022 Financial Results and Corporate Update Conference Call. (Operator Instructions) [...]

Published
2022

42. Alimera Completes Recruitment for its Landmark NEW DAY Study

Subjects
Fluocinolone acetonide, Vascular endothelial growth factor, Fluocinolone, Industry hiring, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2023

43. Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress

Subjects
Fluocinolone acetonide, Ophthalmology, Fluocinolone, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with [...]

Published
2023

45. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIENA in the Nordic Countries

Subjects
Fluocinolone acetonide, Fluocinolone, Marketing, Advertising, marketing and public relations, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better [...]

Published
2023

46. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN(R) in the Nordic Countries

Subjects
Fluocinolone acetonide, Fluocinolone, Marketing, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2023

47. Alimera Sciences Announces 2022 Financial Results and Business Update

Subjects
Fluocinolone acetonide -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Company earnings/profit, General interest, News, opinion and commentary, Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners [...]

Published
2023

48. Alimera Sciences Announces 2022 Financial Results and Business Update

Subjects
Fluocinolone acetonide -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Company earnings/profit, Banking, finance and accounting industries, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision [...]

Published
2023

49. Alimera Sciences reports Q3 EPS (60c), two estimates (52c)

Subjects
Company earnings/profit, Business, News, opinion and commentary, Iluvien (Medication)
Abstract

Reports Q3 revenue $12.153M, three estimates $12.37M. 'The third quarter marks continued improvement in top line revenue from ILUVIEN as we recover from the challenges of the COVID-19 pandemic, with [...]

Published
2021

50. Q1 2022 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences First Quarter 2022 Financial Results and Corporate Update Conference Call. (Operator Instructions) [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results